Visalytics
Visalytics
approved EB-2 (NIW)

Research Professor

Biotechnologies · Ethiopia · 2025-01-13

Processing Time
87 days
Decision Date
2025-01-13
This case is from a publicly available case study. Case studies tend to feature successful outcomes and may not reflect the full range of petition results.

Proposed Endeavor

The petitioner proposes to continue research integrating advanced computational techniques and artificial intelligence to decode complex biological mechanisms and identify new drug targets. This work focuses on streamlining drug discovery processes and improving treatment efficacy for complex diseases such as Acute Myeloid Leukemia (AML).

Framework Evaluation

3 of 3 criteria met
1 Substantial Merit and National Importance Met

The research was recognized as a critical and emerging technology essential for U.S. national competitiveness and healthcare innovation.

2 Well-positioned to Advance the Endeavor Met

The petitioner's Ph.D., publication record, citation count, and history of securing research funding demonstrated the ability to lead the proposed work.

3 On Balance, Beneficial to Waive Job Offer Met

The urgency of AI-driven pharmaceutical innovation and the petitioner's unique expertise made the waiver beneficial to the United States.

Why This Petition Was Approved

The petition was approved based on the petitioner's record of 8 peer-reviewed journal articles and 2 abstracts which garnered 97 citations. Evidence also included the completion of 10 peer reviews for scientific journals and documentation of major research funding from the Ministry of Innovation and Technology (MinT). These achievements satisfied all three Dhanasar prongs by demonstrating the national importance and well-positioned nature of the researcher.

Evidence

Evidence Types
Peer Reviewed Publications
Citations
Reference Letters Independent
Grants
Judging Experience
Government Alignment

Similar Cases

Associate Professor

Biotechnology · Sudan

WeGreened EB-2 (NIW) approved
22 days 2023-08-01
The petitioner proposes to utilize biotechnological research techniques paired with molecular, pharmacological, and microbiological methods to discover novel drugs for the treatment of non-communicable diseases such as cancer and Alzheimer’s disease. This work focuses on enhancing drug efficacy and efficiency to develop therapeutics that reverse symptoms and alleviate healthcare and economic burdens.
View Case

Consultant

Engineering · India

WeGreened EB-2 (NIW) approved
New Jersey 45 days 2025-01-16
The petitioner proposes to continue research on developing advanced machine learning, artificial intelligence, and language modeling frameworks by integrating data-driven methods with domain knowledge. This work aims to address key challenges in drug development and healthcare, specifically focusing on accelerating drug discovery, optimizing clinical trials, and enhancing manufacturing efficiency.
View Case

Others

Biotechnology · China

WeGreened EB-2 (NIW) approved
Georgia 67 days 2025-05-14
The petitioner proposes to develop advanced artificial intelligence models and algorithms to improve early disease diagnosis and predict patient responses to new drugs and combination therapies. This work focuses on enhancing diagnostic precision and treatment effectiveness to accelerate drug discovery and optimize healthcare outcomes. The endeavor specifically aims to benefit vulnerable populations, including infants and the elderly, through optimized medical interventions.
View Case

Others

Pharmaceuticals · South Korea

WeGreened EB-2 (NIW) approved
54 days 2025-03-24
The petitioner proposes to continue her research in pharmaceutical science by integrating advanced technologies and computational approaches to develop novel drug candidates. Her work focuses on improving drug delivery systems to create more effective, affordable, and stable medications for chronic diseases including cancer, diabetes, hypertension, and neurodegenerative diseases.
View Case

Frequently Asked Questions

A approved EB-2 NIW (I-140) petition means USCIS determined the petitioner met the eligibility requirements. For appealed cases, "sustained" means the appeal reversed a prior denial. The petitioner can proceed to the next step in the immigration process.

Browse More Cases

More approved cases More Biotechnology cases More cases from Ethiopia

Case data sourced from publicly available petition decisions and case studies. Decision date: 2025-01-13.

Browse all cases
View Original

At a Glance

Outcome approved
Processing 87 days
Criteria Met 3 / 3
Evidence Types 6

EB-2 (NIW) Case Data

Scraped Case Data

Total Cases 3,813
Success Rate 53.7%
Sustained 2,046
Dismissed 1,671

Related Pages

EB-2 (NIW) Overview EB-2 (NIW) in Ethiopia All EB-2 (NIW) Cases EB-2 (NIW) Dashboard Endeavor Search

Get Case Insights

Compare your profile against thousands of real petition outcomes. Join the waitlist for personalized analysis.

Join Waitlist